Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACBM Stock Summary
Top 10 Correlated ETFs
ACBM
In the News
ACBM Financial details
Company Rating
Neutral
Market Cap
153.11M
Income
-15.79M
Revenue
896.5K
Book val./share
0.01
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
28 Dec 2018
P/E
-12.83
Forward P/E
-
PEG
-0.01
P/S
512.92
P/B
311.09
P/C
-
P/FCF
-1118.28
Quick Ratio
2.03
Current Ratio
4.19
Debt / Equity
0.31
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.27
EPS next Y
-
EPS next Q
-
EPS this Y
5500%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
18.62%
Revenue Q/Q
-
EPS Q/Q
0.3%
-
-
-
-
SMA20
-25.79%
SMA50
-19.43%
SMA100
-34.72%
Inst Own
-
Inst Trans
-
ROA
-1855%
ROE
-2094%
ROC
-23.93%
Gross Margin
26%
Oper. Margin
-3999%
Profit Margin
-3999%
Payout
-
Shs Outstand
60.04M
Shs Float
30.04M
-
-
-
-
Target Price
-
52W Range
2.14-4.5
52W High
-36.25%
52W Low
+27.5%
RSI
10.18
Rel Volume
0.21
Avg Volume
471
Volume
101
Perf Week
-16.39%
Perf Month
-39%
Perf Quarter
-36.25%
Perf Half Y
-36.25%
-
-
-
-
Beta
0.95672
-
-
Volatility
0.25%, 0.57%
Prev Close
0.79%
Price
2.55
Change
0.79%
ACBM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-09-30 | 2018-09-30 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.01 | 0.17 | 0 | 0.01 | 0.02 | |
Net income per share | 0 | 0.01 | -0.01 | 0 | -0.14 | |
Operating cash flow per share | -0.01 | 0 | 0 | 0 | 0.01 | |
Free cash flow per share | -0.01 | 0 | 0 | 0 | 0.01 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
Tangible book value per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
Share holders equity per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 183.51M | 185.4M | 185.79M | 185.79M | 250.35M | |
Enterprise value | 183.51M | 185.54M | 185.83M | 185.79M | 250.31M | |
P/E ratio | -81.63K | 441.79 | -499.96 | -1.58K | -32.52 | |
Price to sales ratio | 359.82 | 23.13 | 959.96 | 270.05 | 209.06 | |
POCF ratio | -396.05 | -1.32K | -3.11K | -931.45 | 836.36 | |
PFCF ratio | -396.05 | -1.32K | -3.11K | -931.45 | 836.36 | |
P/B Ratio | 358.88 | 149.26 | 232.75 | 270.88 | 388.92 | |
PTB ratio | 358.88 | 149.26 | 232.75 | 270.88 | 388.92 | |
EV to sales | 359.81 | 23.15 | 960.19 | 270.06 | 209.02 | |
Enterprise value over EBITDA | -81.63K | 359.89 | -439.58 | -1.42K | -32.53 | |
EV to operating cash flow | -396.05 | -1.32K | -3.11K | -931.48 | 836.21 | |
EV to free cash flow | -396.05 | -1.32K | -3.11K | -931.48 | 836.21 | |
Earnings yield | 0 | 0 | 0 | 0 | -0.03 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.07 | 0.19 | 0.17 | 0.46 | 0.18 | |
Debt to assets | 0.07 | 0.16 | 0.14 | 0.31 | 0.15 | |
Net debt to EBITDA | 0.19 | 0.27 | -0.11 | -0.05 | 0.01 | |
Current ratio | 14.83 | 6.14 | 7.88 | 3.12 | 7.71 | |
Interest coverage | 0 | 140.75 | -213.19 | -25.67 | -1.81K | |
Income quality | 206.11 | -0.33 | 0.16 | 1.7 | -0.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.1 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 4.41 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0.77 | 0 | 6.39 | |
Graham number | 0 | 0.07 | 0.05 | 0.03 | 0.2 | |
ROIC | 0 | 0.29 | -0.41 | -0.12 | -14.13 | |
Return on tangible assets | 0 | 0.28 | -0.4 | -0.12 | -10.11 | |
Graham Net | 0 | 0.01 | 0.01 | 0 | 0.01 | |
Working capital | 511.33K | 1.24M | 767.93K | 661.17K | 614.76K | |
Tangible asset value | 511.33K | 1.24M | 798.24K | 685.87K | 643.71K | |
Net current asset value | 511.33K | 1.24M | 745.58K | 661.17K | 589.05K | |
Invested capital | 0.07 | 0.11 | 0.06 | 0.04 | 0.08 | |
Average receivables | 0 | 0 | 0 | 0 | 299K | |
Average payables | 3.96K | 3.96K | 15.57K | 24.28K | 25.47K | |
Average inventory | 0 | 573.3K | 1.01M | 908.28K | 469K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 182.27 | |
Days payables outstanding | 0.48 | 0.37 | 47.95 | 17.08 | 10.19 | |
Days of inventory on hand | 0 | 58.28 | 1.77K | 647.74 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 2 | |
Payables turnover | 765 | 982.1 | 7.61 | 21.37 | 35.81 | |
Inventory turnover | 0 | 6.26 | 0.21 | 0.56 | 0 | |
ROE | 0 | 0.34 | -0.47 | -0.17 | -11.96 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0.01 | 0 | 0 | 0 | |
Net income per share | -0.05 | -0.07 | -0.07 | -0.07 | -0.07 | |
Operating cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
Free cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
Cash per share | 0 | 0 | 0.01 | 0 | 0 | |
Book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Tangible book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Share holders equity per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 227.48M | 264.45M | 240.17M | 255.18M | 239.57M | |
Enterprise value | 227.33M | 264.4M | 239.85M | 255.2M | 239.58M | |
P/E ratio | -19.01 | -17.16 | -15.28 | -15.96 | -14.93 | |
Price to sales ratio | 0 | 442.22 | 804.58 | 0 | 0 | |
POCF ratio | -3.52K | -4.37K | 916.21 | -737.99 | -4.5K | |
PFCF ratio | -3.52K | -4.37K | 916.21 | -737.99 | -4.5K | |
P/B Ratio | 400.34 | 410.82 | 373.38 | 443.88 | 486.76 | |
PTB ratio | 400.34 | 410.82 | 373.38 | 443.88 | 486.76 | |
EV to sales | 0 | 442.14 | 803.53 | 0 | 0 | |
Enterprise value over EBITDA | -76.01 | -68.63 | -61.05 | -63.86 | -59.73 | |
EV to operating cash flow | -3.52K | -4.37K | 915.01 | -738.06 | -4.5K | |
EV to free cash flow | -3.52K | -4.37K | 915.01 | -738.06 | -4.5K | |
Earnings yield | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.11 | 0.18 | 0.13 | 0.16 | 0.31 | |
Debt to assets | 0.1 | 0.15 | 0.12 | 0.14 | 0.24 | |
Net debt to EBITDA | 0.05 | 0.01 | 0.08 | -0.01 | 0 | |
Current ratio | 10.12 | 7.71 | 10.3 | 7.7 | 4.19 | |
Interest coverage | -16.8K | -19.07K | -18.8K | -18.94K | -8.04K | |
Income quality | 0.02 | 0.02 | -0.07 | 0.09 | 0.01 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 4.21 | 8.44 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 6.57 | 13.16 | 0 | 0 | |
Graham number | 0.11 | 0.13 | 0.13 | 0.12 | 0.11 | |
ROIC | -9.82 | -7.08 | -296.32 | -6.34 | -6.79 | |
Return on tangible assets | -4.75 | -5.06 | -5.39 | -5.97 | -6.23 | |
Graham Net | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Working capital | 561.95K | 614.76K | 614.03K | 545.45K | 462.47K | |
Tangible asset value | 568.22K | 643.71K | 643.22K | 574.89K | 492.16K | |
Net current asset value | 561.95K | 589.05K | 594.64K | 532.46K | 455.94K | |
Invested capital | 0.01 | 0.08 | 0.07 | 0.07 | 0.06 | |
Average receivables | 0 | 299K | 448.25K | 298.5K | 288.5K | |
Average payables | 14.07K | 21.13K | 13.1K | 7.5K | 17.95K | |
Average inventory | 448K | 224K | 0 | 148K | 296K | |
Days sales outstanding | 0 | 90 | 90 | 0 | 0 | |
Days payables outstanding | 0 | 5.26 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 1 | 1 | 0 | 0 | |
Payables turnover | 0 | 17.1 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -5.26 | -5.99 | -6.11 | -6.95 | -8.15 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ACBM Frequently Asked Questions
What is Acro Biomedical Co., Ltd. stock symbol ?
Acro Biomedical Co., Ltd. is a US stock , located in Fishers of In and trading under the symbol ACBM
What is Acro Biomedical Co., Ltd. stock quote today ?
Acro Biomedical Co., Ltd. stock price is $2.55 today.
Is Acro Biomedical Co., Ltd. stock public?
Yes, Acro Biomedical Co., Ltd. is a publicly traded company.